UBS Maintains Neutral Stance on Blue Owl Capital (OWL)

Strive Masiyiwa

Founder of Econet Global, a philanthropist writing on entrepreneurship and finance in Africa.

UBS has reiterated its Neutral rating for Blue Owl Capital Inc. (NYSE:OWL), setting a price target of $9.50. Despite some potential upside, the firm's analysis indicates that the uncertainties surrounding private credit growth and business development companies make a significant reacceleration unlikely. UBS believes that overcoming these challenges to achieve a sustainable low-to-mid-teens fee-related earnings compound annual growth rate through 2028 will be difficult for the company.

UBS Keeps Neutral Outlook on Blue Owl Capital Amidst Market Uncertainties

On June 11, 2026, the financial services giant UBS confirmed its 'Neutral' rating for Blue Owl Capital Inc. (NYSE:OWL), a prominent alternative asset management firm. The bank established a price target of $9.50 per share. This decision comes after a thorough bull-bear assessment, which highlighted that while Blue Owl Capital might possess some inherent growth potential, significant upward movement is currently hampered by lingering uncertainties within the private credit sector and the performance of business development companies.

UBS's comprehensive analysis suggests that the stock is likely to trade within a confined range, as the prevailing 'bear points' currently outweigh the 'bull points'. The firm indicated that a more optimistic outlook on Blue Owl Capital would necessitate a clearer path to achieving a consistent low-to-mid-teens compound annual growth rate in fee-related earnings. This objective, according to UBS, presents a considerable challenge for the company to surmount in the period leading up to 2028.

Following a recent dip from its peak valuation, Blue Owl Capital's shares are presently trading at approximately 9.9 times UBS's projected distributable earnings per share for 2027, and 9.4 times broader market estimates. UBS observed a slight easing of pressure on OWL shares in recent weeks, accompanied by a modest, albeit low-conviction, increase in investor interest. Blue Owl Capital, a key player in alternative asset management, operates across three core business segments: credit, real assets, and GP Strategic Capital. The company specializes in delivering private capital solutions to businesses and offers distinctive alternative investment avenues to a diverse clientele, including institutional investors, individual wealth managers, and insurance companies.

From a journalist's perspective, UBS's reaffirmation of a neutral rating on Blue Owl Capital provides a valuable snapshot of the cautious sentiment pervading certain segments of the financial market. While Blue Owl Capital operates in the dynamic and often lucrative alternative asset management space, the report underscores the importance of sector-specific headwinds, particularly in private credit and business development. It highlights that even for established players, sustained growth requires overcoming formidable challenges and demonstrating consistent, robust financial performance. This analysis serves as a reminder that investment decisions, especially in complex financial instruments, should always be underpinned by a thorough understanding of both macro and microeconomic factors, urging investors to look beyond immediate upside and consider long-term viability and risk profiles.

you may like

youmaylikeicon
Uniswap's UNI Token Sees Significant Gains as Standard Chartered Predicts $100 by 2030

Uniswap's UNI Token Sees Significant Gains as Standard Chartered Predicts $100 by 2030

By Nouriel Roubini
Bunge Stock Rating Adjusted: From 'Buy' to 'Hold' Amidst Near Record Highs

Bunge Stock Rating Adjusted: From 'Buy' to 'Hold' Amidst Near Record Highs

By Mariana Mazzucato
Navan: A Strong Near-Term Performer with Long-Term AI Risks

Navan: A Strong Near-Term Performer with Long-Term AI Risks

By Michele Ferrero
Amazon: A Giant Continuously Expanding Its Empire

Amazon: A Giant Continuously Expanding Its Empire

By Strive Masiyiwa
Novo Nordisk: A Pharmaceutical Leader Navigating Competitive Pressures and Valuation

Novo Nordisk: A Pharmaceutical Leader Navigating Competitive Pressures and Valuation

By Strive Masiyiwa
United Natural Foods: A Turnaround Story with Significant Upside Potential

United Natural Foods: A Turnaround Story with Significant Upside Potential

By Lisa Jing
Blue Bird Stock: Reconsidering Investment Amidst Market Overheating (Hold Rating)

Blue Bird Stock: Reconsidering Investment Amidst Market Overheating (Hold Rating)

By Morgan Housel
GE Aerospace: Strong Fundamentals and Growth Prospects

GE Aerospace: Strong Fundamentals and Growth Prospects

By Suze Orman
Eikon Therapeutics Faces Lock-Up Expiry Risks Despite Promising Clinical Strategy

Eikon Therapeutics Faces Lock-Up Expiry Risks Despite Promising Clinical Strategy

By Michele Ferrero
Market Dynamics and Fund Performance in Q1 2026

Market Dynamics and Fund Performance in Q1 2026

By David Rubenstein
Nexstar Media Group: Legal Challenges and Undervalued Potential

Nexstar Media Group: Legal Challenges and Undervalued Potential

By David Rubenstein
Dogecoin's Potential 8% Surge: Analyst Predicts Upside if Key Support Holds

Dogecoin's Potential 8% Surge: Analyst Predicts Upside if Key Support Holds

By Michele Ferrero
Unlocking Value: The Nexstar Media Group Investment Case

Unlocking Value: The Nexstar Media Group Investment Case

By Robert Kiyosaki
Michael Burry: SpaceX Valuation 'Bedeviled,' Despite Market Rally

Michael Burry: SpaceX Valuation 'Bedeviled,' Despite Market Rally

By Nouriel Roubini
GM's New Silverado Redefines Truck Market with Enhanced Power and Tech

GM's New Silverado Redefines Truck Market with Enhanced Power and Tech

By Robert Kiyosaki